HOB Biotech Group (SHA:688656) subsidiary Hunan Haooubo Biopharmaceutical obtained four medical device registration certificates from Hunan province's food and drug administrator.
The approvals were for four diagnostic kits using magnetic particle chemiluminescence technology to test for antibodies related to melanoma differentiation-associated gene 5, gastric parietal cells, C1q and intrinsic factor, according to a Tuesday filing with the Shanghai bourse.
The registrations are valid until 2030.
Shares of the company rose 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.